The primary activity is contribution to the GABA-A receptor chloride channel. The standalone summary separates this mechanism from disease association, context-dependent synapse organization, urinary-fraction detection and unresolved developmental/localization claims. The current manual set has 42 ACCEPT, nine MODIFY, eight UNDECIDED and seven KEEP_AS_NON_CORE judgments. No NEW assertion is proposed.
The important source distinctions are documented in the source guide, with all original contexts in the source archive. In particular, a human host does not identify the species of an expressed clone; beta2/3-reactive labeling is not beta2-specific; NAS background is not a direct assay; and current short-product sequences are not silently equated to historical 314/373-residue constructs. Verified ancestral placements remain distinct from current donor-list snapshots.
Native fetch, genuine raw/exported/seed reconciliation, target-cache quotation validation, history, schema/GOA/status checks and rendering remain pending. No canonical GABRB2 files or normal sources have been authored by this private proposal.
GABRB2 supplies a beta subunit to the pentameric GABA-A receptor. Human alpha1/beta2/gamma2 structures place beta2 at the GABA-binding interfaces and in the shared ion-channel architecture. Patch-clamp measurements of the engineered receptor, with wild-type comparisons, connect that architecture to GABA-activated currents and bicuculline sensitivity. These observations support the specific GABA-A receptor and GABA-gated chloride-channel refinements; they do not require an independently functioning native beta2 pore. The intracellular-loop engineering also prevents assigning the structural construct to a natural splice accession (PMID:29950725(https://pubmed.ncbi.nlm.nih.gov/29950725/)). Human Thr287Pro experiments separately distinguish impaired surface delivery from impaired currents in mutant-containing receptors, while retaining wild-type and mixed-receptor comparators (PMID:27789573(https://pubmed.ncbi.nlm.nih.gov/27789573/)).
Native human-brain assemblies provide an independent setting for beta2 participation. The alpha1-selected receptors came from neurosurgical material outside the epileptic foci and include beta2-containing and mixed beta2/beta3 assemblies. Selection of alpha1-containing receptors, unresolved mixed positions and missing splice identities limit generalization. Those data do not directly establish beta2 binding to neuroligin-2 or a beta2/beta2 lamotrigine site (PMID:39843743(https://pubmed.ncbi.nlm.nih.gov/39843743/)). Postsynaptic membrane localization describes an important deployment rather than an exclusive compartment: beta2/3-reactive rat labeling also supplies extrasynaptic context, with antibody and species limits (PMID:9464994(https://pubmed.ncbi.nlm.nih.gov/9464994/)).
Natural-product identity and experimental construct identity require separate treatment. Current UniProt records and the four verified FASTAs give 512, 474, 313 and 372 residues, with P47870-2 displayed. The original splice study reports short experimental forms of 314 and 373 residues, recovered through human-brain transcript work and investigated using engineered expression systems. Those historical lengths are retained without inventing an explanation for the one-residue differences. The short experimental forms lacked TM4 but generated currents with alpha1, so the architecture alone cannot establish loss of channel contribution. The brain transcripts, minigene variants, C-terminal tags and T365A comparison are distinct observations (PMID:19763268(https://pubmed.ncbi.nlm.nih.gov/19763268/); UniProt P47870).
Synapse organization is supported in defined experimental settings. Beta2-containing receptors expressed in HEK cells supported functional contacts with rat medium spiny neurons; that co-culture demonstrates a receptor-assembly contribution without isolating a beta2-only adhesive mechanism (PMID:23909897(https://pubmed.ncbi.nlm.nih.gov/23909897/)). In a separate mouse-subunit/neuronal study, beta2 extracellular-domain competition reduced VGAT-positive contact co-localization. Activity was demonstrated in other receptor co-culture experiments, not in that competition arm. Bicuculline produced no statistically significant difference in contact counts; this is not proof of an exactly zero effect. The presynaptic ligand and direct in-vivo mechanism remain unresolved (PMID:27129275(https://pubmed.ncbi.nlm.nih.gov/27129275/)).
The remaining uncertainty is specific rather than a rejection of experimental curation. Mouse beta2 cochlear evidence concerns progressive loss after initially normal efferent development, and the accessible abstract cannot resolve all four distinct developmental transfers (PMID:17021187(https://pubmed.ncbi.nlm.nih.gov/17021187/)). Beta2/3-reactive surface labeling does not resolve the beta2-specific dendritic-spine claim (PMID:25025157(https://pubmed.ncbi.nlm.nih.gov/25025157/)). The accessed vesicle-transport abstract emphasizes gamma2 without resolving the beta2 donor assertion (PMID:25172774(https://pubmed.ncbi.nlm.nih.gov/25172774/)). None of these access limits establishes that the full original lacks the curator's evidence. The urinary-fraction row supplies one peptide without a recovered sequence, limiting conclusions about modern splice identity, vesicle topology or biogenesis (PMID:19056867(https://pubmed.ncbi.nlm.nih.gov/19056867/)).
Additional original reading supersedes the earlier UNDECIDED judgment for the PMID:33234346 negative-regulation row. The complete main text and captions/table explicitly distinguish CLPTM1-mediated retention and reduced transmission from the beta2-containing receptor cargo; SHISA7 is the actor in the described kinetic and targeting effects. That source therefore does not support assigning its negative-regulatory process to GABRB2. The original NAS assertion remains in the archive, with a source-specific REMOVE judgment and a claim-specific MISCITED reference assessment. This is not a general conclusion that beta2 cannot influence transmission regulation, and it does not reinterpret the underlying primary experiments (PMID:33234346(https://pubmed.ncbi.nlm.nih.gov/33234346/)). Current totals are 42 ACCEPT, nine MODIFY, seven UNDECIDED, seven KEEP_AS_NON_CORE and one REMOVE; the four previously checked evidence excerpts, single core, natural products and all other decisions are unchanged. Earlier notes record the knowledge available at their date and remain intact.
The earlier private-stage counts and pending-acquisition statements above are historical. Genuine native acquisition now produced 66 annotations in the 16-column export and an untouched 66-row seed. Every machine field and all four natural products match the accepted inputs. The 33-source set consists of nine main files, nine exact published GABRA1 files and fifteen missing-only PMID acquisitions; existing source bytes were preserved. The urine atom is restored at the verified raw 57 to native 43 join. All four evidence excerpts now match their genuine caches exactly, with only a source newline retained in the ten-word PMID:27789573 excerpt. No quotation is duplicated here.
Native acquisition recovered the original PMID:17021187(https://pubmed.ncbi.nlm.nih.gov/17021187/) main text. Its Methods, Results and Discussion were read completely within the extraction. Beta2-null efferent terminals form normally at P10 and are fully developed by P21, then degenerate by six weeks; later cochlear and neuronal changes likewise concern maintenance of the mature system. The four developmental transfers are now marked over-annotated on that source-specific basis, without asserting that beta2 never participates in development. The extraction does not supply full figure images/captions, quantitative Table1 cells or supplements. This supersedes the earlier abstract-only uncertainty and does not change the separate beta3 interpretation.
Newly recovered PMID:27789573(https://pubmed.ncbi.nlm.nih.gov/27789573/) Methods confirm human alpha1, beta2 and gamma2S cDNAs in HEK293T cells with surface-expression and whole-cell recording assays. Its existing receptor/localization decisions are unchanged; figure images and exact current beta2 splice mapping remain unverified. Current actions are 42 ACCEPT, nine MODIFY, seven KEEP_AS_NON_CORE, three UNDECIDED, four MARK_AS_OVER_ANNOTATED and one REMOVE, with no NEW annotation. Native history, scoped validation, computed status and private rendering are the next checks.
Default schema, ontology, reference and best-practice validation passed with zero advisories. Strict GOA reconciliation confirms all 66 incoming annotations, with no NEW assertion. The native status audit computed COMPLETE; its initial INITIALIZED mismatch is retained in the execution record, and only the computed status was applied. Native CREATE history and the private rendered review passed. The three remaining UNDECIDED localization judgments are preserved. All 33 scientific source files and the original machine files remain exact after authored curation. The generated GO-term-cache companion is accounted for separately from the scientific sources.
Human beta2 receptor assays concern assembled channels, with beta2 contributing binding interfaces and pore structure (PMID:29950725(https://pubmed.ncbi.nlm.nih.gov/29950725/)). The accepted receptor function and specific channel refinements retain this assembly scope; the original source relationships remain unchanged. The core contribution statement does not posit an autonomous native beta2 channel.
The age-resolved mouse observations distinguish normal initial efferent innervation from later terminal degeneration and maintenance of sensory cells and neurons (PMID:17021187(https://pubmed.ncbi.nlm.nih.gov/17021187/)). Short exact excerpts now anchor each of the four existing source-specific over-annotation judgments. A separate excerpt identifies CLPTM1 as the actor regulating receptor trafficking and transmission (PMID:33234346(https://pubmed.ncbi.nlm.nih.gov/33234346/)). These additions preserve all actions and avoid repeating quotations in this journal.
The human splice literature supplies two complementary observations: a 114-base-pair transcript insertion and brain expression (PMID:7707873(https://pubmed.ncbi.nlm.nih.gov/7707873/)), and differing rundown of recombinant long- versus short-form receptors during repeated GABA stimulation (PMID:16983389(https://pubmed.ncbi.nlm.nih.gov/16983389/)). The new reference findings remain abstract-scoped and do not equate historical product names with current accessions. Artificial beta2 homomers respond to histamine with a reported EC50 of 212 micromolar; the heteromer arm demonstrates modulation of GABA responses, preserving the contextual non-core interpretation (PMID:18281286(https://pubmed.ncbi.nlm.nih.gov/18281286/)).
The unresolved beta2-specific spine and transport-vesicle records remain access/attribution questions. The available evidence does not establish that those are field-wide biological unknowns, so no BIOLOGY knowledge-gap assertion is added. All earlier dated journal entries are preserved as the record of the evidence available at the time.
Default validation and strict GOA reconciliation passed with zero advisories. All 66 original contexts and three UNDECIDED judgments remain; the status audit confirms COMPLETE. Native EDIT history, private rendering and scoped whitespace checks passed. The eleven current excerpts are exact cache substrings, with all per-paper totals at or below 25 words including repetitions. The 33 scientific sources, generated cache companion, original CREATE history and earlier journal prefix remain exact.